Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Surveys and Questionnaires 7Nivolumab 5atezolizumab 3Radiosurgery 3Blood Specimen Collection 3pertuzumab 2pembrolizumab 2pazopanib 2cemiplimab 2amminedichloro(2-methylpyridine)platinum(II) 2alectinib 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Drug Therapy 2Capecitabine 2tepotinib 1talazoparib 1selpercatinib 1pralsetinib 1ponatinib 1pemigatinib 1palbociclib 1motexafin gadolinium 1montanide ISA 51 1mannide monooleate 1itacitinib 1ipatasertib 1fludarabine 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × MLN 8237 × Breast × Clear all
NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

University of Illinois at Chicago

Phase 1 Completed
28 enrolled
BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡